Haifa Kathrin Al-Ali - Universitatsklinikum Halle (Saale)

基本信息

浏览量：95

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 244 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Prognostic Impact of the Bone Marrow Tumor Microenvironment, HLA-I and HLA-Ib Expression in MDS and CMML Progression to Saml

Marcus Bauer,Nadja Jaekel, Andreas Wilfer,Anja Haak, Markus Eszlinger,Katalin Kelemen,Monika Haemmerle,Haifa Kathrin Al-Ali,Barbara Seliger,Claudia Wickenhauser

ONCOIMMUNOLOGYno. 1 (2024)

引用0浏览0WOS引用

FRACTION: Protocol of a Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment of the German MPN Study Group (GSG-MPN)

Susanne Isfort,Nikolas von Bubnoff,Haifa Kathrin Al-Ali,Heiko Becker, Thorsten Götze,Philipp le Coutre,Martin Griesshammer, Claudia Moskwa,Luisa Wohn, Johanna Riedel,Francesca Palandri,Kirsi Manz,Andreas Hochhaus,Konstanze Döhner,Florian H. Heidel

Annals of Hematologypp.1-11, (2024)

引用0浏览0WOS引用

Association of Immune Evasion in Myeloid Sarcomas with Disease Manifestation and Patients’ Survival

Marcus Bauer,Astrid Monecke,Hubert Hackl, Andreas Wilfer,Nadja Jaekel,Hendrik Blaeker,Haifa Kathrin Al-Ali,Barbara Seliger,Claudia Wickenhauser

FRONTIERS IN IMMUNOLOGY (2024)

引用0浏览0WOS引用

ROP-ET: a Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2B in Essential Thrombocythemia Patients with Limited Treatment Options

ANNALS OF HEMATOLOGY（2024）

引用0浏览0WOS引用

MoReLife – Real-Life Data Support the Potential of Momelotinib As a Safe and Effective Treatment Option for Cytopenic Myelofibrosis Patients

Stefanie Jilg,Juliana Schwaab,Katja Sockel,Carl C. Crodel,Valeska Brueckl,Frank Stegelmann, Madlen Jentzsch,Daniel Sasca, Margarete Moyses,Stephan Fuhrmann, Daniel Gundel, Madlen Caduc,Lino L. Teichmann, Florian Heidel,Haifa K. Al-Ali, Petro E. Petrides

Annals of Hematologypp.1-13, (2024)

引用0浏览0WOS引用

POSTER: MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients with Myelofibrosis (MF) Treated with Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Haifa Al-Ali,Ruben Mesa,J. E. Hamer-Maansson,Evan Braunstein,Claire Harrison

Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia (2023): S194-S194

引用0浏览0引用

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

Pankit Vachhani,Andrew Perkins,John Mascarenhas,Haifa Kathrin Al‐Ali,Jean‐Jacques Kiladjian,Sonia Cerquozzi, Jarosław Dybko,Regina García Delgado,Jesus Hernández Rivas,Holger Hebart,Zhujun Huang,Cecile M. Krejsa,Hope Qamoos,Jesse McGreivy, Wayne P. Rothbaum,Srđan Verstovšek,Alessandro M. Vannucchi

HemaSphereno. S3 (2023): e05521ca-e05521ca

引用0浏览0引用

Financial Influence on Medical Decisions in Germany - A Review of the Reasons andState of Research on Economization in Inpatient Care

Sara Lena Lueckmann, Grit Boehme,Felix Krueger, Sonja Hiemer,Haifa-Kathrin Al-Ali,Amelie Wuppermann

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFTno. 14 (2023): 916-920

引用0浏览0引用

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS

Haifa Kathrin Al-Ali,Ruben Mesa,J.E. Hamer-Maansson,Evan Braunstein,Claire Harrison

HemaSphereno. S3 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn